Small cell lung cancer: Past, present, and future

Estelamari Rodriguez, Rogerio C. Lilenbaum

Research output: Contribution to journalReview articlepeer-review

80 Scopus citations


Small cell lung cancer (SCLC) accounts for about 10% to 15% of all lung cancers. It is characterized by its rapid doubling time, high rate of dissemination, and increased sensitivity to chemotherapy and radiation. Although the incidence of SCLC has been steadily decreasing over time, it remains a serious public health problem given its aggressive clinical behavior and the lack of effective therapies. This review looks at the evolution of SCLC treatment and the standard treatments that are currently available, including platinum-based combination chemotherapy, hyperfractionated thoracic radiation, and prophylactic cranial irradiation. The development of novel therapies for SCLC has been lagging behind, but completed clinical trials and ongoing investigations are helping us define what will be the best therapeutic targets for this disease.

Original languageEnglish (US)
Pages (from-to)327-334
Number of pages8
JournalCurrent oncology reports
Issue number5
StatePublished - Sep 2010


  • Radiation
  • Small cell lung cancer
  • Targeted therapies

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Small cell lung cancer: Past, present, and future'. Together they form a unique fingerprint.

Cite this